By Fineline Cube Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced that China’s National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational mRNA mpox vaccine, making it the world’s first mRNA-based mpox vaccine candidate to receive regulatory green lights from both the U.S. FDA and China’s Center for Drug Evaluation (CDE).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval |
| Product | mRNA mpox vaccine (investigational) |
| Indication | Prevention of mpox infection |
| Approval Date | 24 Jun 2026 |
| Global Status | First mRNA mpox vaccine approved for clinical trials in both US and China |
Vaccine Profile & Mechanism of Action
- Platform: mRNA-based vaccine technology
- Target: Multiple orthopoxvirus antigens including mpox virus
- Innovation: Demonstrates broad-spectrum cross-reactivity against multiple orthopoxviruses (mpox, vaccinia, variola, ectromelia)
- Comparative Advantage: Generates significantly higher levels of mpox-neutralizing antibodies compared to China’s Tian Tan strain (live attenuated smallpox vaccine)
- Patient Benefit: Shows superior immunogenicity versus licensed replication-deficient mpox vaccines overseas, offering enhanced protection for immunocompromised individuals including those who are HIV-positive
Preclinical Evidence
| Parameter | Ab&B mRNA Vaccine | Tian Tan Strain (China) | Licensed Replication-Deficient Vaccines (Overseas) |
|---|---|---|---|
| Neutralizing Antibody Levels | Significantly higher | Baseline | Moderate |
| Cross-Reactivity | Broad-spectrum against multiple orthopoxviruses | Limited | Narrow |
| Suitability for Immunocompromised | High (non-replicating platform) | Contraindicated | Moderate |
| Safety Profile | Favorable (mRNA platform) | Risk of adverse events | Generally favorable |
Preclinical studies demonstrated that Ab&B’s mRNA vaccine induced substantially higher neutralizing antibody titers while maintaining a favorable safety profile inherent to non-replicating vaccine platforms.
Market Impact & Strategic Outlook
- Global Health Security: With mpox remaining a public health concern following the 2022-2023 global outbreak, next-generation vaccines with improved safety profiles are critical for pandemic preparedness
- Commercial Potential: As the first dual-approved mRNA mpox vaccine candidate, Ab&B is positioned to capture significant market share in both Western and Chinese markets
- Competitive Edge: The vaccine’s superior immunogenicity and suitability for immunocompromised populations address key limitations of existing smallpox/mpox vaccines
- Development Timeline: Clinical trials will now proceed to evaluate safety and efficacy in human subjects, with potential accelerated pathways given the public health importance
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, manufacturing challenges, and competitive dynamics.-Fineline Info & Tech